GPNMB and Parkinson disease: In this context, the work published by Brendza et al. showed that GPNMB loss did not modify changes in a remyelination mouse model or in two different mouse models of PD-like α-syn pathology (synthetic human α-syn PFFs and AAV1/2-CMV/CBA virus vector driving human mutant A53T α-syn) [195].